SCHEMBL3665013

SCHEMBL3665013

c1ccc(CCc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 11/20 1.00
ROCK2 O75116 10/20 1.00
GSK3B P49841 10/20 1.00
AURKB Q96GD4 6/20 1.00
PIM1 P11309 4/20 0.80
AURKA O14965 4/20 0.80
PRKACA P17612 4/20 0.80
GSK3A P49840 4/20 0.80
CDK5 Q00535 4/20 0.80
PRKAA1 Q13131 4/20 0.80
ROCK1 Q13464 4/20 0.80
DYRK1A Q13627 4/20 0.80
RPS6KA3 P51812 3/20 0.80
CDK1 P06493 3/20 0.80
CDK2 P24941 3/20 0.80
MARK3 P27448 3/20 0.80
MAPK1 P28482 3/20 0.80
PRKCD Q05655 3/20 0.80
CDC42BPA Q5VT25 3/20 0.80
DAPK3 O43293 3/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3667957 0.93 ROCK2 (1.00) JAK2ROCK2GSK3BAURKBPIM1
SCHEMBL3667547 0.89 JAK2 (1.00) JAK2ROCK2GSK3BAURKBPIM1
SCHEMBL4293081 0.84 JAK2 (1.00) JAK2ROCK2GSK3BAURKBPIM1
SCHEMBL3670230 0.82 JAK2 (1.00) JAK2ROCK2GSK3BAURKBPIM1
SCHEMBL3667820 0.81 ROCK2 (0.71) JAK2ROCK2GSK3BAURKBPIM1
SCHEMBL3667117 0.81 JAK2 (0.70) JAK2ROCK2GSK3BAURKBPIM1
SCHEMBL3670175 0.80 JAK2 (0.67) JAK2ROCK2GSK3BAURKBPIM1
SCHEMBL3666181 0.78 ROCK2 (1.00) JAK2ROCK2GSK3BAURKBPIM1
SCHEMBL4291757 0.77 AURKB (0.74) JAK2ROCK2GSK3BAURKBPIM1
SCHEMBL3668143 0.77 AURKB (1.00) JAK2ROCK2GSK3BAURKBPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 JAK2 102/4885ROCK2 48/4885GSK3B 1/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 JAK2 102/4885ROCK2 48/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.